The Gastritis drugs in development market research report provides comprehensive information on the therapeutics under development for Gastritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Gastritis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Gastritis and features dormant and discontinued products.

GlobalData tracks 17 drugs in development for Gastritis by 14 companies/universities/institutes. The top development phase for Gastritis is phase iii with five drugs in that stage. The Gastritis pipeline has 17 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Gastritis pipeline products market are: Addpharma, GNT Pharma and Trio Medicines.

The key targets in the Gastritis pipeline products market include Prostaglandin E Synthase (Microsomal Glutathione S Transferase 1 Like 1 or Microsomal Prostaglandin E Synthase 1 or p53 Induced Gene 12 Protein or PTGES or EC 5.3.99.3), Potassium Transporting ATPase Alpha Chain 1 (Gastric H(+)/K(+) ATPase Subunit Alpha or Proton Pump or ATP4A or EC 7.2.2.19), and Free Radical.

The key mechanisms of action in the Gastritis pipeline product include Prostaglandin E Synthase (Microsomal Glutathione S Transferase 1 Like 1 or Microsomal Prostaglandin E Synthase 1 or p53 Induced Gene 12 Protein or PTGES or EC 5.3.99.3) Inhibitor with two drugs in Preclinical. The Gastritis pipeline products include four routes of administration with the top ROA being Oral and two key molecule types in the Gastritis pipeline products market including Small Molecule, and Monoclonal Antibody.

Gastritis overview

Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years). Gastritis can be caused by medications such as ibuprofen, aspirin, or naproxen on long periods of consumption; excess intake of alcohol; Helicobacter pylori infection; certain autoimmune disorders; bile reflux; substance abuse (cocaine); consumption of corrosive or caustic substances such as poisons; extreme stress; viral infections; and trauma. The symptoms of gastritis may include loss of appetite, nausea and vomiting, abdominal pain, and black stools. Treatment includes use of antacids, histamine 2 (H2) antagonists, and proton pump inhibitors.

For a complete picture of Gastritis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.